Abstracts tagged "Arthroplasty and systemic lupus erythematosus (SLE)"

Abstract Number: 1834 • 2015 ACR/ARHP Annual Meeting
Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?
Marco González-Contreras¹, Javier Merayo-Chalico¹, Rigoberto Ortíz-Hernández², Diana Gómez-Martín² and Jorge Alcocer-Varela², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: In patients with systemic lupus erythematosus (SLE), persistent joint activity and treatment with glucocorticoids are associated with musculoskeletal complications, including hip osteonecrosis. About 30%…
Abstract Number: 2573 • 2012 ACR/ARHP Annual Meeting
Arthoplasty Rates Increased Among US Patients with Systemic Lupus Erythematosus: 1991-2005
Christina Mertelsmann-Voss¹, Ting Jung Pan², Huong Do², Mark P. Figgie³ and Lisa A. Mandl⁴, ¹Pediatric Rheumatology, Hospital for Special Surgery, Cornell University, New York, NY, ²Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Orthopedics, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: There is little data regarding patterns of arthroplasty use in patients with Systemic Lupus Erythematosus (SLE). This study evaluates trends in total joint replacement…
Abstract Number: 2443 • 2012 ACR/ARHP Annual Meeting
Pain and Function Outcomes in Systemic Lupus Erythematosus Hip and Knee Arthroplasty
Ummara Shah¹, Lisa A. Mandl², Mark P. Figgie³, Michael Alexiades⁴ and Susan M. Goodman², ¹Division of Rheumatology, New York University School of Medicine, NYC, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Orthopedics, Hospital for Special Surgery, New York, NY, ⁴Orthopaedics, Hospital for Special Surgery, New York, NY
Background/Purpose: There is little information on Systemic Lupus Erythematosus (SLE) patients undergoing total joint arthroplasty (TJA). The purposes of this study were to determine the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].